• Home
  • Contributors
  • Glossary
  • Subscribe

Bioasis Technologies Inc.

The Science of Melanotransferrin (p97)

From the category archives:

prescription medicine

Controversy-plagued Genzyme Refuses Sanofi Acquisition

by Mahesh on September 7, 2010

Report Says Canadians Spend as much On Prescription Drugs As The Americans; So What’s All The Fuss About?

by Mahesh on June 24, 2010

Links Between Alzheimer’s and Antidepressants

by Henry on June 23, 2010

Biopharma’s Way Of Doing Business – Keep Your Eyes On The Ball!

by Mahesh on May 6, 2010

Global Shortage Of Parkinson’s Drug Shows Vulnerability On Neurological Disease Front

by Mahesh on April 2, 2010

How Healthcare Reform Affects Pharma and Biotech

by Mahesh on April 1, 2010

Can You Please Turn My Lead Into Gold? – Out-Licensing As Focusing Strategy (Part 2)

by Mahesh on March 4, 2010

Can You Please Turn My Lead Into Gold? – Out-Licensing As Focusing Strategy (Part 1)

by Mahesh on March 3, 2010

President Obama Moves Ahead With New Measures To Finalize Healthcare Bill

by Mahesh on February 24, 2010

PhRMA CEO Steps Down Amidst Unstable Health Reform Process

by Mahesh on February 17, 2010

← Previous Entries

  • Pages

    • Contributors
    • Glossary
    • Robin (Rob) B. Hutchison, Chairman & CEO
  • Recent Posts

    • Sleep Disorder Predicts Dementia?
    • Controversy-plagued Genzyme Refuses Sanofi Acquisition
    • Mental Exercises Affect Alzheimer’s Disease
    • Blood-Brain Barrier Carriers – the Next Frontier for CNS Diseases?
    • What If Amyloid Actually Protected The Brain?
  • Categories

    • ADDL (1)
    • age-related neurodegenerative disease (150)
    • Alzheimer's Research (194)
    • amyloid beta deposits/plaques (64)
    • amyloid protein vaccination (4)
    • antidepressants (4)
    • axon deterioration (53)
    • BioAsis (106)
    • biosecurity (1)
    • biosimilar therapies (23)
    • biotechnology (151)
    • bioterrorism (1)
    • Blood Brain Barrier (53)
    • CEO (2)
    • cholinergic effects (1)
    • chronic neurological diseases (81)
    • Citizen Petition (4)
    • dementia (71)
    • diabetes (5)
    • DNA (5)
    • Dr. Wilf Jefferies (3)
    • FDA (14)
    • Frontotemporal Dementia (19)
    • Genentech (9)
    • Health reform (17)
    • Huntington's Disease (11)
    • Huntington’s Disease (5)
    • immunotherapy (1)
    • LDT (1)
    • Lewy Body Variant (5)
    • Melanotransferrin (64)
    • mental illness (51)
    • MOCA (2)
    • Neurological Diseases (163)
    • neurological disorders (68)
    • New Studies (18)
    • Not-for-Profit Organisations (9)
    • P97 (81)
    • Parkinson's (22)
    • Parkinson's Disease (32)
    • Parkinson’s (8)
    • personalized medicine (7)
    • Pfizer (36)
    • Pharma (31)
    • prescription medicine (13)
    • research cutbacks (31)
    • Research tools (4)
    • SEB (2)
    • Subsequent Entry Biologics (2)
    • tau tangles (30)
    • team members (3)
    • Uncategorized (29)
    • Unconventional treatments (4)
    • Vascular Dementia (23)
    • Wyeth (21)
  • Recent Comments

    • Blood-Brain Barrier Carriers - the Next Frontier for CNS Diseases? on The Blood-Brain Barrier: A Major Hurdle For Neurological Drug Delivery
    • What If Amyloid Actually Protected the Brain? on Will Anti-Amyloid Failures Change Pharma Approach?
    • Will Anti-Amyloid Failures Failures Change Pharma Approach? on Bapineuzumab’s Phase II Results Published – AD Drug Fails Expectations
    • Willa Zavala on Be Careful of Some Home Remedies for Alzheimer’s Disease
    • Biomarker Tests Can Revolutionize Alzheimer's Diagnosis and Treatment on biOasis CEO Rob Hutchison provides shareholder update
  • Archives

    • September 2010 (5)
    • August 2010 (17)
    • July 2010 (19)
    • June 2010 (18)
    • May 2010 (16)
    • April 2010 (17)
    • March 2010 (17)
    • February 2010 (15)
    • January 2010 (15)
    • December 2009 (16)
    • November 2009 (16)
    • October 2009 (17)
    • September 2009 (18)
    • August 2009 (18)
    • July 2009 (18)
    • June 2009 (15)
    • May 2009 (13)
    • April 2009 (13)
    • March 2009 (10)
    • February 2009 (16)
    • January 2009 (4)
    • September 2008 (1)
  • Categories

    • ADDL
    • age-related neurodegenerative disease
    • Alzheimer's Research
    • amyloid beta deposits/plaques
    • amyloid protein vaccination
    • antidepressants
    • axon deterioration
    • BioAsis
    • biosecurity
    • biosimilar therapies
    • biotechnology
    • bioterrorism
    • Blood Brain Barrier
    • CEO
    • cholinergic effects
    • chronic neurological diseases
    • Citizen Petition
    • dementia
    • diabetes
    • DNA
    • Dr. Wilf Jefferies
    • FDA
    • Frontotemporal Dementia
    • Genentech
    • Health reform
    • Huntington's Disease
    • Huntington’s Disease
    • immunotherapy
    • LDT
    • Lewy Body Variant
    • Melanotransferrin
    • mental illness
    • MOCA
    • Neurological Diseases
    • neurological disorders
    • New Studies
    • Not-for-Profit Organisations
    • P97
    • Parkinson's
    • Parkinson's Disease
    • Parkinson’s
    • personalized medicine
    • Pfizer
    • Pharma
    • prescription medicine
    • research cutbacks
    • Research tools
    • SEB
    • Subsequent Entry Biologics
    • tau tangles
    • team members
    • Uncategorized
    • Unconventional treatments
    • Vascular Dementia
    • Wyeth

Get smart with the Thesis WordPress Theme from DIYthemes.

WordPress Admin